Radiofrequency ablation is best treatment for benign bone tumor

Main Category: Radiology / Nuclear Medicine
Article Date: 30 Sep 2003 - 0:00 PDT


Contact: Maureen Morley
mmorley@rsna.org
630-590-7754
Radiological Society of North America

Minimally invasive procedure treats painful osteoid osteoma

OAK BROOK, Ill. (USA) - Radiofrequency ablation (RFA) should be the treatment of choice for the majority of patients suffering with a benign but painful bone tumor known as osteoid osteoma, according to research published in the October issue of Radiology.

The study, from Massachusetts General Hospital in Boston, is the first large-scale research that shows RFA to be preferable to open surgery as the primary treatment for this type of bone tumor.

'This study is significant because it proves that surgery is not necessary for the treatment of osteoid osteoma in most patients,' said the study's lead author, Daniel Rosenthal, M.D., professor of radiology at Harvard Medical School in Boston.

Osteoid osteomas represent about 10 percent of benign bone tumors. They are most commonly found in children and young adults and are often difficult to diagnose. Although such tumors rarely exceed 1.5 cm in diameter (a little over half an inch) and have little or no growth potential, they can cause severe pain.

'Our average patient is 17 years old, and three out of four patients are male,' Dr. Rosenthal said. 'These individuals tradionally are unable to participate in any sport or recreational activity and many require round-the-clock medication.'

Minimally invasive therapies such as RFA have been explored as an alternative to the two traditional treatments for osteoid osteoma: surgery and management through anti-inflammatory medication.

When treated operatively, the tumor can be difficult to identify, and incomplete removal may lead to recurrence. Cutting out a tumor from a weight-bearing bone may also involve a prolonged recuperation. Long-term use of anti-inflammatory medications is unappealing to many patients because of negative side effects.

Interventional radiologists perform RFA by inserting a CT-guided wire to the tumor site and transmitting an electrical current to destroy the lesion. Following the two-hour procedure, most patients are able to resume daily activities immediately.

Dr. Rosenthal's study followed 263 patients undergoing RFA for osteoid osteoma over an 11-year period.

Patients in the study included 184 males and 79 females, ages 2 to 56. Most of the tumors were located in the patients' lower extremities, and the majority of procedures were initial tumor treatments.

Researchers were able to perform long-term follow-up of at least 24 months on 126 patients. Of the procedures performed on those patients, 112 were a complete clinical success (a success rate of 89 percent), meaning patients were free of pain, taking no medications and requiring no additional procedures.

The success rate of re-treatments--in which the procedure was performed after a prior unsuccessful RFA or surgical treatment--was 60 percent. Patient age, sex, and lesion size and location did not appear to affect the probability of a clinically successful outcome.

'This study shows that radiofrequency ablation can be performed as an outpatient procedure on the great majority of patients with osteoid osteoma,' Dr. Rosenthal said. 'The success rate is high, the complication rate low, and the recovery brief.'

Radiology is a monthly scientific journal devoted to clinical radiology and allied sciences. The journal is edited by Anthony V. Proto, M.D., School of Medicine, Virginia Commonwealth University, Richmond, Virginia. Radiology is owned and published by the Radiological Society of North America, Inc.

The Radiological Society of North America (RSNA) is an association of more than 33,000 radiologists, radiation oncologists and related scientists committed to promoting excellence through education and by fostering research, with the ultimate goal of improving patient care. The Society's headquarters are located at 820 Jorie Boulevard, Oak Brook, Ill. 60523-2251.
(http://www.rsna.org).

'Osteoid Osteoma: Percutaneous Treatment with Radiofrequency Energy.' Collaborating with Dr. Rosenthal on this paper were Francis J. Hornicek, M.D., Ph.D., Martin Torriani, M.D., Mark C. Gebhardt, M.D., and Henry J. Mankin, M.D.

• Additional
• References
• Citations